Q2 2018 FINANCIAL RESULTS
SALES WORLDWIDE

$7.8 billion on organic basis*

FULL-YEAR 2018 GUIDANCE RAISED
$2.85 TO $2.91 ADJUSTED EPS, REFLECTING 15% GROWTH.2

HELPING PEOPLE LIVE FULLY
WITH LIFE-CHANGING TECHNOLOGY

NEW U.S. FDA APPROVALS
• MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device
• XIENCE Sierra®, the newest generation of our gold-standard coronary stent system
• Advisor™ HD Grid Mapping Catheter, Sensor Enabled® designed to create highly-detailed maps of the heart
• Afidion® Analyzer, a state-of-the-art multi-assay rapid test system for diabetes management

NEW DEVELOPMENTS
• Launched Ensure® Max Protein in the U.S. to help refill the body with 30 grams of high-quality protein and 1 gram of sugar
• XIENCE Sierra® received national reimbursement in Japan

NEW DATA
• Expanded real-world evidence from 250,000+ FreeStyle Libre users showed higher frequency scanning is associated with improved glucose control3

FORWARD-LOOKING STATEMENTS
Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*Organic sales growth: Reflects the prior-year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017; Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017, and is subject to foreign exchange for all full financial data and reconciliation of our U.S. GAAP measures, please see our press release dated July 18, 2018. **Full-year 2018 GAAP EPS guidance of $1.34 to $1.40, 58% growth.


STRONG PERFORMANCE IN CORE BUSINESS SEGMENTS1

DIAGNOSTICS
+6.6%

MEDICAL DEVICES
+8.2%

NUTRITION
+6.4%

ESTABLISHED PHARMACEUTICALS
+12.3%

1Sales on organic basis*

NEW U.S. FDA APPROVALS
• MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device
• XIENCE Sierra®, the newest generation of our gold-standard coronary stent system
• Advisor™ HD Grid Mapping Catheter, Sensor Enabled® designed to create highly-detailed maps of the heart
• Afidion® Analyzer, a state-of-the-art multi-assay rapid test system for diabetes management

NEW DEVELOPMENTS
• Launched Ensure® Max Protein in the U.S. to help refill the body with 30 grams of high-quality protein and 1 gram of sugar
• XIENCE Sierra® received national reimbursement in Japan

NEW DATA
• Expanded real-world evidence from 250,000+ FreeStyle Libre users showed higher frequency scanning is associated with improved glucose control3

FORWARD-LOOKING STATEMENTS
Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*Organic sales growth: Reflects the prior-year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017; Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017, and is subject to foreign exchange for all full financial data and reconciliation of our U.S. GAAP measures, please see our press release dated July 18, 2018. **Full-year 2018 GAAP EPS guidance of $1.34 to $1.40, 58% growth.


HELPING PEOPLE LIVE FULLY
WITH LIFE-CHANGING TECHNOLOGY

NEW U.S. FDA APPROVALS
• MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device
• XIENCE Sierra®, the newest generation of our gold-standard coronary stent system
• Advisor™ HD Grid Mapping Catheter, Sensor Enabled® designed to create highly-detailed maps of the heart
• Afidion® Analyzer, a state-of-the-art multi-assay rapid test system for diabetes management

NEW DEVELOPMENTS
• Launched Ensure® Max Protein in the U.S. to help refill the body with 30 grams of high-quality protein and 1 gram of sugar
• XIENCE Sierra® received national reimbursement in Japan

NEW DATA
• Expanded real-world evidence from 250,000+ FreeStyle Libre users showed higher frequency scanning is associated with improved glucose control3

FORWARD-LOOKING STATEMENTS
Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*Organic sales growth: Reflects the prior-year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017; Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017, and is subject to foreign exchange for all full financial data and reconciliation of our U.S. GAAP measures, please see our press release dated July 18, 2018. **Full-year 2018 GAAP EPS guidance of $1.34 to $1.40, 58% growth.


HELPING PEOPLE LIVE FULLY
WITH LIFE-CHANGING TECHNOLOGY

NEW U.S. FDA APPROVALS
• MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device
• XIENCE Sierra®, the newest generation of our gold-standard coronary stent system
• Advisor™ HD Grid Mapping Catheter, Sensor Enabled® designed to create highly-detailed maps of the heart
• Afidion® Analyzer, a state-of-the-art multi-assay rapid test system for diabetes management

NEW DEVELOPMENTS
• Launched Ensure® Max Protein in the U.S. to help refill the body with 30 grams of high-quality protein and 1 gram of sugar
• XIENCE Sierra® received national reimbursement in Japan

NEW DATA
• Expanded real-world evidence from 250,000+ FreeStyle Libre users showed higher frequency scanning is associated with improved glucose control3

FORWARD-LOOKING STATEMENTS
Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*Organic sales growth: Reflects the prior-year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017; Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017, and is subject to foreign exchange for all full financial data and reconciliation of our U.S. GAAP measures, please see our press release dated July 18, 2018. **Full-year 2018 GAAP EPS guidance of $1.34 to $1.40, 58% growth.


HELPING PEOPLE LIVE FULLY
WITH LIFE-CHANGING TECHNOLOGY

NEW U.S. FDA APPROVALS
• MitraClip® NTR and MitraClip® XTR, the latest versions of our leading heart valve repair device
• XIENCE Sierra®, the newest generation of our gold-standard coronary stent system
• Advisor™ HD Grid Mapping Catheter, Sensor Enabled® designed to create highly-detailed maps of the heart
• Afidion® Analyzer, a state-of-the-art multi-assay rapid test system for diabetes management

NEW DEVELOPMENTS
• Launched Ensure® Max Protein in the U.S. to help refill the body with 30 grams of high-quality protein and 1 gram of sugar
• XIENCE Sierra® received national reimbursement in Japan

NEW DATA
• Expanded real-world evidence from 250,000+ FreeStyle Libre users showed higher frequency scanning is associated with improved glucose control3

FORWARD-LOOKING STATEMENTS
Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.